Nicardipine
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Using the txgnn-pipeline skill to orient this task — this is a report-generation step within the TxGNN pipeline for the PhTxGNN (Philippines) project. I’ll now generate the evaluation report from the Evidence Pack.
Nicardipine: From Hypertension to Multifactorial Pulmonary Hypertension
One-Sentence Summary
Nicardipine is a dihydropyridine-type calcium channel blocker (CCB) widely used internationally for hypertension management and hypertensive emergencies; however, it has no registered product in the Philippines. The TxGNN model’s top prediction is that it may be effective for pulmonary hypertension with unclear multifactorial mechanism (WHO Group 5), with a prediction score of 99.26%. Supporting this direction, there are currently no registered clinical trials and no directly relevant publications, placing the evidence entirely at model-prediction level.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No Philippines registration; internationally used for hypertension and hypertensive emergencies |
| Predicted New Indication | Pulmonary hypertension with unclear multifactorial mechanism (WHO Group 5) |
| TxGNN Prediction Score | 99.26% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Philippines Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacology, Nicardipine is an L-type voltage-gated calcium channel blocker (CCB) of the dihydropyridine subclass. It acts by blocking calcium influx into vascular smooth muscle cells, producing arterial vasodilation and reducing peripheral vascular resistance — with a more selective vascular profile and less negative inotropic effect than older CCBs.
The theoretical basis for TxGNN’s prediction lies in this pulmonary vasodilatory effect. In WHO Group 1 Pulmonary Arterial Hypertension (PAH), roughly 10% of idiopathic cases respond positively to acute vasoreactivity testing (AVT); these patients are candidates for high-dose CCB therapy (nifedipine, diltiazem, amlodipine). Nicardipine, sharing the same class, could theoretically contribute in this narrow, AVT-positive cohort.
However, the predicted indication here is WHO Group 5 PH — pulmonary hypertension arising from unclear or multifactorial causes (haematological disorders, systemic disorders, metabolic diseases). CCBs have no established role in Group 5 PH, and the pathophysiological pathways diverge fundamentally from Group 1 PAH. The TxGNN model likely arrives at this prediction via indirect connections in the knowledge graph (e.g., shared disease nodes with hypertension), but the clinical extrapolation is speculative. This prediction carries a high risk of graph-level artefact rather than true mechanistic signal.
Clinical Trial Evidence
Currently no related clinical trials registered for pulmonary hypertension with unclear multifactorial mechanism (WHO Group 5) in combination with Nicardipine.
Literature Evidence
Currently no related literature directly linking Nicardipine to pulmonary hypertension with unclear multifactorial mechanism.
Note: A PubMed search for the rank-2 indication (pulmonary hypertension owing to lung disease and/or hypoxia) returned 20 results, but all retrieved articles address general hypoxia biology (HIF-1α signalling, altitude physiology, cognitive effects of hypoxia, tumour microenvironment) and contain no data on Nicardipine efficacy in pulmonary hypertension. They are not included as supporting evidence.
Philippines Market Information
Nicardipine currently has no registered products in the Philippines (data cutoff: 2026-05-05). There are no FDA Philippines authorisation numbers, no approved dosage forms, and no approved indications on record.
Safety Considerations
Please refer to the package insert for safety information.
No DDI data was retrieved. Key warnings and contraindications are not available in this Evidence Pack and require retrieval from the official prescribing information.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a high TxGNN prediction score (99.26%), the evidence base for Nicardipine in WHO Group 5 pulmonary hypertension is entirely absent — no clinical trials, no publications, and no mechanistic studies directly support this indication. The underlying disease group (Group 5 PH) has heterogeneous, poorly characterised aetiology for which CCBs carry no guideline-recommended role; the prediction most likely reflects indirect graph connectivity rather than true therapeutic signal.
To proceed, the following is needed:
- MOA confirmation: Query DrugBank API (DB00622) to formally document Nicardipine’s mechanism of action and target profile
- Safety data: Retrieve FDA Philippines or equivalent prescribing information to complete key warnings, contraindications, and drug interaction profile
- Indication re-evaluation: Assess whether the more mechanistically coherent target should be AVT-positive Group 1 PAH (where CCBs do have a guideline role), rather than Group 5 PH
- Preclinical evidence search: A focused literature search using MeSH terms [nicardipine] AND [pulmonary hypertension] AND [vasoreactivity] is warranted before any further development steps
- Philippines registration pathway: If evidence were to strengthen, a regulatory pre-consultation with FDA Philippines would be needed, given zero current market presence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.